Debunking the notion that boosters don't reduce Omicron symptomatic infections. Another new study from Qatar shows they are halved medrxiv.org/content/10.110… matched >400,000 people with mRNA vaccines 2 vs 3-dose
Booster vaccine effectiveness vs Omicron infections 62% (2 dose 32%) @UKHSA in people without Prior Covid assets.publishing.service.gov.uk/government/upl…
and higher with Prior Covid, hybrid immunity, as seen in all studies
Since the booster protection vs Delta symptomatic infections was 95% and vs Omicron it is ~50%, that is a 10-fold increase in breakthroughs
Which is why there is the misperception that there is no booster protection from infections or transmission w/ Omicron
*when there is*
They are cut in half; 90% vs hospitalizations
I watched @billmaher and @bariweiss last night @RealTimers and it is so obvious they are not in touch with the data and, unfortunately, propagating misinformation
Adding this important study, the largest household (~12,000) contact study for Omicron and Delta infections and *impact of booster* (3rd) dose vaccination:
Infections were reduced OR 0.54, CI 0.40-0.71)
Transmission risk reduced OR: 0.72, CI: 0.56-0.92) medrxiv.org/content/10.110…
First post of this thread, Figure label correction by authors (Moderna, panel B, not Pfizer in both panels)
And full discussion of these findings erictopol.substack.com/p/where-do-we-…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)